Skip to content
Biodatica
Start free

Aminex Therapeutics, Inc.

Tucson, Arizona

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

4d agoTrial registeredJul 15, 2026Source filing (opens the source filing in a new tab)

Momentum

76no change

Momentum 76 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

~2months

The model puts this company near the end of its last raise.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,008 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Jan 26, 2026

    Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer · RECRUITING · sponsor: Aminex Therapeutics, Inc. · Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    ClinicalTrials.gov · NCT07287917 (opens the source filing in a new tab)

  2. Filing

    Form D · $15M

    Dec 5, 2025

    Aminex Therapeutics, Inc. · private raise, self-reported by the issuer

    SEC EDGAR · 0001470831-25-000383 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources